Debulking surgery for malignant tumors: the current status, evidence and future perspectives

Abstract Debulking surgery, also called cytoreductive is a resection of the tumor as much possible and an intended incomplete for unresectable malignant tumors. Since most important principle in surgical oncology complete R0 resection, debulking surgery goes against basic obscures concept operability. However, has been advocated various types advanced tumors, including gynecological cancers, urological gastrointestinal breast cancers other malignancies, with or without adjuvant therapy. Positive data from randomized trials have shown subsets ovarian cancer, renal cell carcinoma, colorectal cancer cancer. recent tended to show controversial results, mainly according survival improvement nonsurgical systemic therapy alone. On hand, still therapeutic role slow-growing borderline such pseudomyxoma peritonei thymomas. The understanding heterogeneity clonal evolution responsible malignancy drug resistance indicates that select patients may obtain prolonged by synergistic effect novel This review aimed describe current status evidence cross-organ manner discuss future perspectives era advances